Panbela Therapeutics Inc
NASDAQ:PBLA

Watchlist Manager
Panbela Therapeutics Inc Logo
Panbela Therapeutics Inc
NASDAQ:PBLA
Watchlist
Price: 0.4401 USD -8.31% Market Closed
Updated: May 19, 2024

Panbela Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Panbela Therapeutics Inc
Research & Development Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Panbela Therapeutics Inc
NASDAQ:PBLA
Research & Development
-$20.6m
CAGR 3-Years
-102%
CAGR 5-Years
-63%
CAGR 10-Years
-54%
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.3B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$6B
CAGR 3-Years
18%
CAGR 5-Years
-3%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-24%
CAGR 5-Years
-19%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.6B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-17%

See Also

What is Panbela Therapeutics Inc's Research & Development?
Research & Development
-20.6m USD

Based on the financial report for Dec 31, 2023, Panbela Therapeutics Inc's Research & Development amounts to -20.6m USD.

What is Panbela Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-54%

Over the last year, the Research & Development growth was 27%. The average annual Research & Development growth rates for Panbela Therapeutics Inc have been -102% over the past three years , -63% over the past five years , and -54% over the past ten years .